The psoriasis therapeutic potential of a novel short laminin peptide C16

Abstract

Abstract Psoriasis is a chronic skin disorder characterized by cutaneous inflammation, keratinocyte hyperproliferation and desquamation formation. There are nearly 10 million patients around the world. Current remedies have potential serious side effects. There is an unmet need for new therapies with better efficacy and less adverse effects. Recently, we found that the C16 peptide derived from extracellular matrix component laminin 111 has the potential for psoriasis therapy. Topical treatment with C16 ameliorates imiquimod (IMQ)-induced psoriasis-like skin inflammation. BALB/c Mice (8-week-old) received a daily topical of IMQ cream (5%; Aldara; 3M Pharmaceuticals) on the shaved back for six consecutive days. The mice developed psoriasis-like skin inflammation and desquamation formation. Topical application of IMQ combining with C16 showed reduced skin inflammation and desquamation. Histology analysis confirmed obvious reduction of inflammatory cell infiltration and acanthosis. In cell culture, C16 also inhibited IMQ-induced keratiocyte proliferation. Since C16 peptide has been found that can bind to α5β1 and αvβ3 integrins, integrins α5β1 and αvβ3 may be involved in the mechanism of psoriasis therapy. Results of ongoing investigation will be presented in the meeting.